Tesamorelin

Tesamorelin is a GHRH Analogue supplied for laboratory research. Stabilized GHRH analogue studied in vitro for pulsatile GH secretion pathway modeling, visceral adipose tissue signaling analysis, and lipid metabolism pathway research.

Tesamorelin is the stabilized GHRH analogue studied as the active compound in the branded product Egrifta. The material here is unformulated tesamorelin for research use only, not an approved medicine.

Tesamorelin is supplied as a lyophilized (freeze-dried) powder — a dehydrated form that keeps the peptide stable during shipping and storage. In the laboratory it is reconstituted (returned to liquid form) using a solvent such as bacteriostatic water, added slowly against the side of the vial, which is then swirled gently — never shaken — until the powder fully dissolves. All handling is for in vitro research use only.

Store the lyophilized Tesamorelin powder at -20°C, protected from light and moisture, where it remains stable long-term. Once reconstituted, keep it refrigerated (2-8°C) and use it within the timeframe appropriate for your research protocol.

Every batch of Tesamorelin is produced to a purity of 99% or higher. Purity and molecular identity are verified using standard analytical methods — high-performance liquid chromatography (HPLC) to measure purity, and mass spectrometry (MS) to confirm the peptide's molecular weight.